As per the latest report by IMARC Group, titled "Oral Proteins and Peptides Market by Drug Type (Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide), Application (Gastric and Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders), and Region 2023-2028," the global oral proteins and peptides market size reached US$ 1.57 Billion in 2022. Oral proteins and peptides are substances that are administered orally, typically in the form of capsules, tablets, or liquid formulations. They have emerged as a breakthrough in the field of drug delivery, offering an alternative to traditional injection-based methods. Their manufacturing involves meticulous formulation techniques to ensure stability and bioavailability. The efficacy of oral proteins and peptides lies in their ability to mimic natural physiological processes. Once administered, these macromolecules interact with specific receptors in the gastrointestinal tract, triggering cellular signaling pathways. This interaction facilitates the transport of the therapeutic molecules across the epithelial barrier and into the systemic circulation, where they can reach their target tissues or organs. By leveraging the body's natural absorption mechanisms, oral delivery offers a convenient and non-invasive route for administering these biologics. The advantages of oral protein and peptide delivery include eliminating the need for injections, thus providing a more patient-friendly experience. This non-invasive approach improves compliance, especially for long-term treatments. Furthermore, oral administration enables self-administration, reducing the burden on healthcare systems. It also offers the potential for improved drug stability and reduced manufacturing costs compared to injectable formulations.
Global Oral Proteins and Peptides Market Trends:
The global oral proteins and peptides market is influenced by several key factors, including the increasing prevalence of chronic diseases, such as diabetes, cancer, and cardiovascular disorders, and advancements in drug delivery technologies and formulations. Furthermore, the growing geriatric population, coupled with the rising awareness about preventive healthcare, has increased the demand for oral protein and peptide-based supplements, thus driving the market growth. Moreover, the extensive research and development (R&D) activities in the biotechnology and pharmaceuticals sectors, focusing on the development of innovative oral protein and peptide therapeutics, are fueling the market growth. Additionally, increasing investments by key market players in the development and commercialization of oral protein and peptide drugs are bolstering the market growth. Besides this, the rising healthcare expenditure and the favorable government initiatives to promote the use of oral protein and peptide therapeutics are contributing to the market growth. Additionally, the growing preference for non-invasive drug delivery methods and the surging awareness about the advantages offered by oral proteins and peptides, such as reduced side effects and improved patient compliance, are strengthening the market growth. Looking forward, the market value is projected to reach US$ 2.67 Billion by 2028, expanding at a CAGR of 8.60% during 2023-2028.
- By the drug type, the market has been segmented into linaclotide, plecanatide, calcitonin, insulin, and octreotide. At present, insulin dominates the market.
- Based on the application, the market has been classified into gastric and digestive disorders, bone diseases, diabetes, and hormonal disorders. Currently, diabetes account for the largest market share.
- On the basis of the region, the market has been categorized into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. At present, North America dominates the market.
- The competitive landscape of the industry has also been examined with some of the key players being Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc.
|Base Year of the Analysis
|Drug Types Covered
||Linaclotide, Plecanatide, Calcitonin, Insulin, Octreotide
||Gastric and Digestive Disorders, Bone Diseases, Diabetes, Hormonal Disorders
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Amryt Pharma Plc, AstraZeneca PLC, Biocon Limited, Novo Nordisk A/S, Oramed Ltd, Proxima Concepts Limited, etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800